Dermata Reports U.S. Trademark Registration for TOME® Brand
Dermata Therapeutics has received U.S. federal trademark registration for its TOME® skincare brand as the company develops its commercial skincare business.
Dermata Therapeutics, Inc. (Nasdaq:DRMA) said on November 18, 2026, that the United States Patent and Trademark Office had granted federal trademark registration for its TOME® brand. The registration number is 8555002.
The San Diego-based company said the registration adds intellectual property protection for its commercial skincare business. Chairman, President and Chief Executive Officer Gerry Proehl said the company has invested resources in developing the TOME brand and that protecting its identity supports Dermata’s commercial strategy.
Dermata also cautioned that statements concerning the adequacy of trademark protection, product launches, market acceptance and potential clinical benefits are subject to risks and uncertainties. The company said registered trademarks may not provide adequate protection for its intellectual property.
Dermata introduced its first TOME product, Foundational Treatment, in August 2026. The company describes it as a once-weekly, professional-grade skincare treatment intended for use at home and designed to improve the appearance of skin texture, tone and overall radiance.
The TOME line uses what Dermata describes as a “wild harvested freshwater sponge,” an ingredient the company associates with skincare products rooted in history and science. Dermata says the brand is intended to offer products that are “powerful, not punishing.”
Dermata plans to launch TOME Clearing Treatment for acne in the first half of 2027. The product remains a planned release, and the company’s forward-looking statements regarding launch timing and commercial performance are subject to risks and uncertainties.
The company said it is working to expand awareness of TOME, encourage consumer adoption and establish the line as a differentiated skincare brand. Dermata also referred to recently announced positive clinical data and photographs from a cosmetic clinical study of Foundational Treatment.
Dermata Therapeutics develops and commercialises direct-to-consumer and professional skincare solutions. The company says it draws on clinical dermatology experience and its proprietary Bioneedle™ technology to develop products for consumer skincare needs. Dermata is headquartered in San Diego, California.
Dermata Therapeutics announced that it had received U.S. federal trademark registration for its TOME® brand from the United States Patent and Trademark Office. The registration number is 8555002.
Dermata Therapeutics announced the registration on November 18, 2026.
Dermata Therapeutics shares trade on Nasdaq under the ticker symbol DRMA.
Dermata Therapeutics said the federal registration strengthens intellectual property protection for its newly launched commercial skincare business. Gerry Proehl, the company’s Chairman, President and Chief Executive Officer, said protecting the brand identity supports the company’s investment in Tome and its commercial strategy.
Dermata Therapeutics develops and commercialises direct-to-consumer and professional skincare solutions. The company says it uses its experience in clinical dermatology and proprietary Bioneedle™ technology to develop skincare products for a range of consumer needs.
Dermata Therapeutics’ first commercial TOME product is Foundational Treatment, which the company launched in August 2026. It is a once-weekly skincare treatment designed to improve the appearance of skin texture, tone and overall radiance, and is intended for consumers to use at home.
Dermata Therapeutics describes TOME as a skincare line focused on products that are “powerful, not punishing”. The products use a wild harvested freshwater sponge, which the company says has evolved over centuries, and are intended for consumers interested in products rooted in history and science.
Dermata Therapeutics plans to launch Clearing Treatment for acne in the first half of 2027. The source describes this as a planned launch rather than a completed product release.
Dermata Therapeutics said it is focused on expanding brand awareness, driving consumer adoption and establishing TOME as a differentiated skincare brand. The company said recently announced positive clinical data and photos from a cosmetic clinical study of TOME Foundational Treatment help support those efforts.
Gerry Proehl said the company believes protecting TOME’s brand identity helps establish the foundation for future product growth as Dermata continues its commercial strategy. Dermata also cautioned that statements about future product launches, market acceptance, clinical benefits and the adequacy of trademark protection are subject to risks and uncertainties, and that actual events or results may differ materially from projections.